Risk factors for mortality and re-admission of children with hematological malignancies to the intensive care unit due to sepsis.

IF 2.2 4区 医学 Q3 HEMATOLOGY
Shlomit Barzilai-Birenboim, David M Zucker, Galia Avrahami, Sarah Elitzur, Salvador Fisher, Sarah Ganem, Gil Gilead, Shai Izraeli, Gili Kadmon, Eytan Kaplan, Aviva Krauss, Elhanan Nahum, Ron Rabinowicz, Jerry Stein, Osnat Tausky, Avichai Weissbach, Talya Wittmann Dayagi, Joanne Yacobovich, Asaf D Yanir
{"title":"Risk factors for mortality and re-admission of children with hematological malignancies to the intensive care unit due to sepsis.","authors":"Shlomit Barzilai-Birenboim, David M Zucker, Galia Avrahami, Sarah Elitzur, Salvador Fisher, Sarah Ganem, Gil Gilead, Shai Izraeli, Gili Kadmon, Eytan Kaplan, Aviva Krauss, Elhanan Nahum, Ron Rabinowicz, Jerry Stein, Osnat Tausky, Avichai Weissbach, Talya Wittmann Dayagi, Joanne Yacobovich, Asaf D Yanir","doi":"10.1080/10428194.2025.2521650","DOIUrl":null,"url":null,"abstract":"<p><p>Children with hematological malignancies, are often hospitalized in pediatric intensive care units (PICU) for sepsis with high mortality and re-admission rates. Risk factors for both are inconsistent. We reviewed data of 190 admissions of children with hematological malignancies to PICU for sepsis. Survival rate (SR) was 85%. Mortality risk factors were: non-complete remission (<i>p</i> < 0.01) and status post-stem cell transplantation (<i>p</i> = 0.02), and best predictors were inotropic drugs (<i>p</i> < 0.01), and Pediatric logistic organ dysfunction-2 (<i>p</i> < 0.01) scores. Patients with viremia had the lowest SR (50%, 0.001). One-quarter of the children were re-admitted due to sepsis, and risk factors were: High-risk (HR) hematological malignancy (<i>p</i> < 0.01) and lack of central venous line (CVL) removal (<i>p</i> < 0.01). Sepsis remains a major cause of death in children with hematological malignancies, and re-admissions are common. Our findings support the recommendation of removing CVL during sepsis and highlight those at the highest risk for sepsis to consider individualized anti-infectious prophylaxis.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-11"},"PeriodicalIF":2.2000,"publicationDate":"2025-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia & Lymphoma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10428194.2025.2521650","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Children with hematological malignancies, are often hospitalized in pediatric intensive care units (PICU) for sepsis with high mortality and re-admission rates. Risk factors for both are inconsistent. We reviewed data of 190 admissions of children with hematological malignancies to PICU for sepsis. Survival rate (SR) was 85%. Mortality risk factors were: non-complete remission (p < 0.01) and status post-stem cell transplantation (p = 0.02), and best predictors were inotropic drugs (p < 0.01), and Pediatric logistic organ dysfunction-2 (p < 0.01) scores. Patients with viremia had the lowest SR (50%, 0.001). One-quarter of the children were re-admitted due to sepsis, and risk factors were: High-risk (HR) hematological malignancy (p < 0.01) and lack of central venous line (CVL) removal (p < 0.01). Sepsis remains a major cause of death in children with hematological malignancies, and re-admissions are common. Our findings support the recommendation of removing CVL during sepsis and highlight those at the highest risk for sepsis to consider individualized anti-infectious prophylaxis.

由于败血症导致的恶性血液病儿童死亡率和再次入院的危险因素。
患有血液系统恶性肿瘤的儿童通常因败血症住院,死亡率和再入院率高。两者的风险因素并不一致。我们回顾了190例因败血症而入院PICU的恶性血液病患儿的资料。生存率(SR) 85%。死亡危险因素为:未完全缓解(p p = 0.02),最佳预测因子为肌力药物(p p p p
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Leukemia & Lymphoma
Leukemia & Lymphoma 医学-血液学
CiteScore
4.10
自引率
3.80%
发文量
384
审稿时长
1.8 months
期刊介绍: Leukemia & Lymphoma in its fourth decade continues to provide an international forum for publication of high quality clinical, translational, and basic science research, and original observations relating to all aspects of hematological malignancies. The scope ranges from clinical and clinico-pathological investigations to fundamental research in disease biology, mechanisms of action of novel agents, development of combination chemotherapy, pharmacology and pharmacogenomics as well as ethics and epidemiology. Submissions of unique clinical observations or confirmatory studies are considered and published as Letters to the Editor
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信